Mayo Clinic Laboratory and pathology research roundup: May 30 - Insights
This week's research roundup feature: Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms.
Mayo Clinic Laboratory and pathology research roundup: April 11 - Insights
This week's Research Roundup feature: A stress-induced cilium-to-PML-NB route drives senescence initiation.
Mayo Clinic Laboratory and pathology research roundup: August 30 - Insights
This week's research roundup features: Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis
Mayo Clinic Laboratory and pathology research roundup: October 25 - Insights
This week's research roundup features: Automated scoring of total inflammation in renal allograft biopsies
Mayo Clinic Laboratory and pathology research roundup: April 18 - Insights
This week's Research Roundup feature: Renal involvement in systemic sclerosis.
Mayo Clinic Laboratory and pathology research roundup: April 25 - Insights
This week's Research Roundup feature: Deficiency of the CD155-CD96 immune checkpoint controls IL-9 production in giant cell arteritis.
Mayo Clinic Laboratory and pathology research roundup: May 23 - Insights
This week's research roundup feature: Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era.
Labor Day Specimen Shipment Alert - Insights
Due to the Labor Day holiday (recognized on Monday, September 5th), Mayo Clinic Laboratories' specimen pickup and delivery schedules will be altered. To ensure that your specimen vitality and turnaround times are not affected, plan ahead.
Mayo Clinic Laboratory and pathology research roundup: May 9 - Insights
This week's research roundup feature: Proprotein Convertase Subtilisin/Kexin Type 6 (PCSK6) is a likely antigenic target in membranous nephropathy and nonsteroidal anti-inflammatory drug use.
Mayo Clinic Laboratory and pathology research roundup: August 15 - Insights
This week's research roundup feature: Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis.